Integral Investment Advisors Inc. Sells 227 Shares of Abbott Laboratories (NYSE:ABT)

Integral Investment Advisors Inc. lessened its holdings in Abbott Laboratories (NYSE:ABT) by 8.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,455 shares of the healthcare product maker’s stock after selling 227 shares during the quarter. Integral Investment Advisors Inc.’s holdings in Abbott Laboratories were worth $326,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Redwood Park Advisors LLC bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at $25,000. Noble Wealth Management PBC acquired a new stake in shares of Abbott Laboratories during the fourth quarter worth $26,000. NewSquare Capital LLC increased its holdings in Abbott Laboratories by 78.4% in the fourth quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker’s stock valued at $27,000 after purchasing an additional 105 shares during the last quarter. WealthTrak Capital Management LLC acquired a new position in Abbott Laboratories in the fourth quarter valued at about $28,000. Finally, Rialto Wealth Management LLC acquired a new position in shares of Abbott Laboratories during the 4th quarter worth about $29,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Transactions at Abbott Laboratories

In related news, Director Sally E. Blount sold 2,600 shares of the business’s stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $129.66, for a total transaction of $337,116.00. Following the transaction, the director now directly owns 34,058 shares in the company, valued at approximately $4,415,960.28. The trade was a 7.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Bank of America increased their price target on shares of Abbott Laboratories from $133.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, March 10th. Wells Fargo & Company lifted their price target on shares of Abbott Laboratories from $136.00 to $147.00 and gave the stock an “overweight” rating in a research report on Thursday, April 17th. Royal Bank of Canada boosted their price target on shares of Abbott Laboratories from $140.00 to $145.00 and gave the company an “outperform” rating in a report on Thursday, April 17th. The Goldman Sachs Group raised their price objective on Abbott Laboratories from $138.00 to $154.00 and gave the stock a “buy” rating in a research note on Tuesday, March 4th. Finally, Wall Street Zen downgraded Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 12th. Four investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $142.59.

Abbott Laboratories Stock Performance

Shares of ABT opened at $133.41 on Tuesday. The stock has a market capitalization of $232.11 billion, a price-to-earnings ratio of 17.44, a PEG ratio of 2.52 and a beta of 0.73. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $141.23. The firm has a fifty day simple moving average of $130.77 and a 200 day simple moving average of $126.01. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Wednesday, April 16th. The healthcare product maker reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $1.07 by $0.02. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.38 billion. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. Research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.